Vildaridge M 50/500
TM Tablets combine Vildagliptin, a DPP-4 inhibitor, with Metformin, a widely used first-line antidiabetic agent. Vildagliptin enhances incretin hormone activity, leading to increased insulin secretion and reduced glucagon levels, while Metformin works by decreasing hepatic glucose production and improving insulin sensitivity. This complementary mechanism helps achieve effective and sustained glycemic control in patients with type 2 diabetes mellitus.
Composition
- Vildagliptin 50 mg
- Metformin Hydrochloride 500 mg
Key Features & Benefits
- Dual Mechanism Control: Targets insulin secretion and insulin resistance
- Improved Glycemic Stability: Helps manage both fasting and post-meal glucose levels
- Good Tolerability Profile: Generally well tolerated in long-term use
- Low Risk of Hypoglycemia: When used appropriately under medical supervision
- Convenient Combination: Reduces pill burden and enhances adherence
Recommended Usage
- To be taken as prescribed by a healthcare professional
- Preferably taken with meals to reduce gastrointestinal discomfort
- Regular monitoring of blood glucose is advised
Safety Information
- Not recommended in patients with severe hepatic or renal impairment
- Monitor liver function periodically during therapy
- Use cautiously in patients with a history of pancreatitis
- Consult a doctor if any adverse effects are observed
Storage Instructions
- Store in a cool, dry place
- Protect from moisture and direct sunlight
- Keep out of reach of children
